Vaishali Pharma DuPont analysis

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.82×0.77×———
1.48×1.53×———
3.4%3.2%———
0.93×0.93×———
1.79×1.79×1.69×1.87×1.95×
6.8%6.4%———
6.2%6.2%———
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VAISHALI₹6.82

Vaishali Pharma Limited

· Unclassified
₹ CrorePeersTEMBOTOTALOSWALSEEDSGROBTEABEARDSELLHINDCONCROWNARTNIRMANMcap ₹44.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×———0.770.82
Interest Burden (Pretax/EBIT) ×———1.531.48
EBIT Margin %———3.233.37
Asset Turnover ×———0.930.93
Financial Leverage (Assets/Equity) ×1.951.871.691.791.79
ROE (5-step product, year-end total equity) %———6.366.82
ROE (owners' profit / average owners' equity) %———6.216.21
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.